Phase I Trial of TGFB2-Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine for Advanced Cancer

Inclusion Criteria: * Histologically confirmed advanced or metastatic non-curable solid tumor (if limited to a single lesion and not a candidate for curative surgery or radiation therapy). * Completed ≥1 conventional therapy. * Clinically indicated surgery or procedure to collect available tumor in sufficient quantity ("golf ball size," pleural or ascites fluid may also be collected) for vaccine processing. * Subjects that have completed all acceptable therapies that are the current standard of care for their respective diseases. * Recovered from all toxicities related to prior therapies. * Subjects with brain metastases treated at least ≥2 months prior to enrollment, without related clinical symptoms and must have a stable neurological exam on the screening evaluation. * ≥1 measurable or evaluable lesion. * Age ≥18 years. * ECOG performance status (PS) 0-1. * Normal organ and marrow function: * Absolute granulocyte count: ≥1,500/mm3 * Platelets: ≥100,000/mm3 * Total bilirubin: ≤2 mg/dL * AST(SGOT)/ALT(SGPT): ≤2x institutional upper limit of normal * Creatinine: \<1.5 mg/dL * Ability to understand and the willingness to sign a written informed consent document. * Negative pregnancy test. Exclusion Criteria: * Surgery involving general anesthesia, chemotherapy, radiotherapy, steroid therapy, or immunotherapy within 4 weeks prior to entering the study. * Patient must not have received any other investigational agents within 30 days prior to study entry. * Patients with known brain metastases unless treated and stable for ≥2 months. * Patients with mucinous adenocarcinoma. * Short term (\<30 days) concurrent systemic steroids ≤ 0.125 mg/kg prednisone per day (maximum 10 mg/day) and bronchodilators (inhaled steroids) are permitted; other steroid regimens and/or immunosuppressives are excluded. Patients requiring steroids following previous CNS radiation for metastatic disease are excluded. * Prior splenectomy. * Prior malignancy (excluding nonmelanoma carcinomas of the skin) unless in remission for ≥2 years. * Kaposi's Sarcoma. * Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * Patients who are pregnant or nursing. * Patients who are HIV positive. * Patients with chronic Hepatitis B and C infection. * Patients with a history of autoimmune diseases.